Recruiting
Phase 2

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT02760030

Conditions

Estrogen Receptor and/or Progesterone Receptor Positive

HER2/Neu Negative

Stage IA Breast Cancer

Stage IB Breast Cancer

Stage IIA Breast Cancer

Eligibility Criteria

Sex: Female

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Fulvestrant

Laboratory Biomarker Analysis

Palbociclib

Questionnaire Administration

Aromatase Inhibitors

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information